# US 2022/0024963 A1 · Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0024963 A1
- Document ID: US20220024963A1
- Status: Published application
- Kind: A1
- Application number: 17/492,301
- Filed: 2021-10-01
- Published: 2022-01-27
- Earliest claimed: 2019-04-01
- Assignees: NuCana plc
- Applicants: NuCana plc
- Inventors: Hugh Griffith; Michaela Serpi; Fabrizio Pertusati; Magdalena Slusarczyk; Samuele Di Ciano
- Web page: https://patentgrep.com/patent/US20220024963A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides to salts of triphosphate phosphoramidates which are useful in the treatment of cancer.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein
R1 is independently at each occurrence selected from: C1-C24-alkyl, C3-C24-alkenyl, C3-C24-alkynyl, C0-C4-alkylene-C3-C8-cycloalkyl and C0-C4-alkylene-aryl;
R2 and R3 are each independently at each occurrence selected from H, C1-C6-alkyl and C1-C3-alkylene-R7; or R2 and R3 together with the atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl group;
R4 is independently at each occurrence H or C1-C4-alkyl;
or R4, a group selected from R2 and R3 and the atoms to which they are attached may form a 3- to 6-membered heterocycloalkyl group;
R5 is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8-cycloalkyl, 3- to 7-membered heterocycloalkyl, C1-C3-alkylene-R5a and C1-C8-alkyl, said aryl being optionally fused to C6-C8-cycloalkyl;
R5a is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8-cycloalkyl, 3- to 7-membered heterocycloalkyl, said aryl being optionally fused to C6-C8-cycloalkyl;
R6 is independently selected from:
R7 is independently at each occurrence selected from aryl, imidazole, indole, SRa, ORa, CO2Ra, CO2NRaRa, NRaRb and NH(═NH)NH2;
R8 is independently selected from H and
Z1 and Z2 are each independently selected from O and S;
R9 is independently selected from H and Me;
Y is independently selected from H, F, Cl and OMe;
X is at each occurrence selected from H and a pharmaceutically acceptable cation; provided that in at least one occurrence X is a pharmaceutically acceptable cation;
wherein any aryl group is either phenyl or naphthyl;
wherein where any of R1, R2, R3, R4, R5 or R7 is an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, that alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally substituted with from 1 to 4 substituents selected from: halo, nitro, cyano, NRaRa, NRaS(O)2Ra, NRaC(O)Ra, NRaCONRaRa, NRaCO2Ra, ORa; SRa, SORa, SO3Ra, SO2Ra, SO2NRaRa, CO2Ra C(O)Ra, CONRaRa, CRaRaNRaRa, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-haloalkyl;
wherein Ra is independently at each occurrence selected from: H and C1-C4-alkyl; and Rb is independently at each occurrence selected from: H, and C1-C4-alkyl and C(O)—C1-C4-alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 3 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 4 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 5 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 6 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 7 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 8 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 9 (depends on 1)

The compound of claim 1, wherein R6 is

### Claim 10 (depends on 1)

The compound of claim 1, wherein R1 is selected from C5-C7-cycloalkyl, C1-C8-alkyl and benzyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is selected from H and C1-C4-alkyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 is H.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R5 is selected from phenyl and naphthyl.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound of formula (I) is selected from:

### Claim 16 (depends on 1)

The compound of claim 1, wherein X is at each occurrence the same and is a metal cation or an ammonium cation.

### Claim 17 (depends on 1)

A method for prophylaxis or treatment of cancer comprising administration to a patient in need of such treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cancer is leukemia.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cancer is a lymphoma.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
